Article Information
History
- January 28, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Maria Frantzi1,*,
- Isabel Heidegger2,
- Marie C. Roesch3,
- Enrique Gomez-Gomez4,
- Eberhard Steiner2,
- Antonia Vlahou5,
- William Mullen6,
- Ipek Guler7,
- Axel S. Merseburger3,
- Harald Mischak1,6 and
- Zoran Culig2
- 1Department of Biomarker Research, Mosaiques Diagnostics, Hannover, Germany
- 2Department of Urology, Medical University of Innsbruck, Innsbruck, Austria
- 3University Hospital Schleswig-Holstein, Campus Lübeck, Department of Urology, Lübeck, Germany
- 4Urology Department, Reina Sofía University Hospital, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), University of Cordoba (UCO), Cordoba, Spain
- 5Systems Biology Center, Biomedical Research Foundation, Academy of Athens, Athens, Greece
- 6Institute of Cardiovascular and Medical Science, University of Glasgow, Glasgow, United Kingdom
- 7Leuven Biostatistics and Statistical Bioinformatics Centre (L-BioStat), Katholiek Universiteit (KU) Leuven, University of Leuven, Leuven, Belgium
- ↵*Address correspondence to:
Dr. Maria Frantzi, Department of Biomarker Research, Mosaiques diagnostics GmbH, Rotenburger Strasse 20, Hannover D-30659, Germany, Phone: +49 51155474429, Fax: +49 51155474431, E-mail: frantzi{at}mosaiques-diagnostics.com
Posted January 28, 2022.
Validation of diagnostic nomograms based on CE-MS urinary biomarkers to distinguish clinically significant prostate cancer
